1. |
Gertz MA. Waldenstrom macroglobulinemia: 2023 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2023, 98(2): 348-358. DOI: 10.1002/ajh.26796.
|
2. |
Groves FD, Travis LB, Devesa SS, et al. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994[J]. Cancer, 1998, 82(6): 1078-1081. DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3.
|
3. |
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. DOI: 10.1182/blood-2016-01-643569.
|
4. |
Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome[J]. Blood, 2012, 119(10): 2205-2208. DOI: 10.1182/blood-2011-04-347690.
|
5. |
Central Vein Occlusion Study Coordinating Center. Baseline and early natural history report. The Central Vein Occlusion Study[J]. Arch Ophthalmol, 1993, 111(8): 1087-1095. DOI: 10.1001/archopht.1993.01090080083022.
|
6. |
中国抗癌协会血液肿瘤专业委员会 中华医学会血液学分会 中国华氏巨球蛋白血症工作组. 淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国指南(2022年版)[J]. 中华血液学杂志, 2022, 43(8): 624-630. DOI: 10.3760/cma.j.issn.0253-2727.2022.08.002.Hematology Oncology Committee of China Anti- Cancer Association, Chinese Society of Hematology, Chinese Medical Association, Chinese Working Group of Walderström Macroglobulinemia. Chinese guideline for diagnosis and treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (2022)[J]. Chin J Hematol, 2022, 43(8): 624-630. DOI: 10.3760/cma.j.issn.0253-2727.2022.08.002.
|
7. |
Pérez-Rueda A. Leukemic retinopathy secondary to hyperviscosity syndrome in acute lymphoblastic leukemia before and after treatment[J]. J Fr Ophtalmol, 2021, 44(3): 477-479. DOI: 10.1016/j.jfo.2020.04.039.
|
8. |
Shrestha S, Poddar E, Bashyal B, et al. Bilateral central retinal vein occlusion as an initial presentation of Waldenstrom macroglobulinemia: a case report[J]. J Med Case Rep, 2023, 17(1): 59. DOI: 10.1186/s13256-023-03778-4.
|
9. |
Hayreh SS, van Heuven WA, Hayreh MS. Experimental retinal vascular occlusion. I. pathogenesis of central retinal vein occlusion[J]. Arch Ophthalmol, 1978, 96(2): 311-323. DOI: 10.1001/archopht.1978.03910050179015.
|
10. |
Schatz MJ, Wilkins CS, Otero-Marquez O, et al. Multimodal imaging of Waldenstrom macroglobulinemia-associated hyperviscosity-related retinopathy treated with plasmapheresis[J/OL]. Case Rep Ophthalmol Med, 2021, 2021: 6816195[2021-12-15]. https://pubmed.ncbi.nlm.nih.gov/34956683/. DOI: 10.1155/2021/6816195.
|
11. |
Baker PS, Garg SJ, Fineman MS, et al. Serous macular detachment in Waldenström macroglobulinemia: a report of four cases[J]. Am J Ophthalmol, 2013, 155(3): 448-455. DOI: 10.1016/j.ajo.2012.09.018.
|
12. |
Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies[J]. J Clin Oncol, 2020, 38(11): 1198-1208. DOI: 10.1200/JCO.19.02314.
|
13. |
Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenström macroglobulinemia[J]. J Clin Oncol, 2018, 36(27): 2755-2761. DOI: 10.1200/JCO.2018.78.6426.
|
14. |
Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase[J]. J Med Chem, 2019, 62(17): 7923-7940. DOI: 10.1021/acs.jmedchem.9b00687.
|
15. |
Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study[J]. Blood, 2020, 136(18): 2038-2050. DOI: 10.1182/blood.2020006844.
|
16. |
Kumar SK, Callander NS, Adekola K, et al. Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology[J/OL]. J Natl Compr Canc Netw, 2024, 22(1D): e240001[2024-01-01]. https://pubmed.ncbi.nlm.nih.gov/38244272/. DOI: 10.6004/jnccn.2024.0001.
|
17. |
Plante MM, Kimbrough EO, Agarwal AK, et al. Hyperviscosity syndrome induced bilateral visual and auditory impairment in therapy resistant Waldenström macroglobulinemia with MYD88 and CXCR4 mutations[J]. J Blood Med, 2023, 14: 639-648. DOI: 10.2147/JBM.S424072.
|
18. |
Chanana B, Gupta N, Azad RV. Case report: bilateral simultaneous central retinal vein occlusion in Waldenström's macroglobulinemia[J]. Optometry, 2009, 80(7): 350-353. DOI: 10.1016/j.optm.2008.12.007.
|
19. |
Thomas EL, Olk RJ, Markman M, et al. Irreversible visual loss in Waldenström's macroglobulinaemia[J]. Br J Ophthalmol, 1983, 67(2): 102-106. DOI: 10.1136/bjo.67.2.102.
|
20. |
Blau-Most M, Gepstein R, Rubowitz A. Bilateral simultaneous central retinal vein occlusion in hyperviscosity retinopathy treated with systemic immunosuppressive therapy only[J]. Am J Ophthalmol Case Rep, 2018, 12: 49-51. DOI: 10.1016/j.ajoc.2018.08.006.
|
21. |
Ratanam M, Ngim YS, Khalidin N, et al. Intravitreal bevacizumab: a viable treatment for bilateral central retinal vein occlusion with serous macular detachment secondary to Waldenström macroglobulinaemia[J]. Br J Haematol, 2015, 170(3): 431-434. DOI: 10.1111/bjh.13307.
|
22. |
Fenicia V, Balestrieri M, Perdicchi A, et al. Intravitreal injection of dexamethasone implant in serous macular detachment associated with Waldenström's disease[J]. Case Rep Ophthalmol, 2013, 4(2): 64-69. DOI: 10.1159/000354066.
|